Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date22 Jul 2021 |
以安慰剂对照评价蛭芎胶囊治疗中风病(缺血性脑卒中,瘀血阻络证)恢复早期安全性和有效性随机、双盲、多中心Ⅱ期临床试验。
[Translation] A randomized, double-blind, multicenter phase Ⅱ clinical trial to evaluate the early safety and efficacy of Zhixiong Capsules in the treatment of stroke (ischemic stroke, blood stasis blocking collaterals) with placebo control.
评价蛭芎胶囊治疗中风病(缺血性脑卒中,瘀血阻络证)恢复早期患者整体结局的安全性和有效性,并进行剂量及疗程探索,推荐Ⅲ期临床试验用药剂量与疗程。
[Translation] To evaluate the safety and efficacy of Zhixiong Capsules in the treatment of stroke (ischemic stroke, blood stasis blocking collaterals) on the overall outcome of patients with early recovery, and to explore the dose and course of treatment.
100 Clinical Results associated with Shanxi Pikang Pharmaceutical Co., Ltd
0 Patents (Medical) associated with Shanxi Pikang Pharmaceutical Co., Ltd
100 Deals associated with Shanxi Pikang Pharmaceutical Co., Ltd
100 Translational Medicine associated with Shanxi Pikang Pharmaceutical Co., Ltd